Hypermethylation of the NLRC5 gene promoter was reported to be the most common epigenetic mechanism associated with reduced MHC-I expression in human cancers and cell lines that could be reversed by 5-Aza treatment [28]. This evidence concerns the gene NLRC5 and cancer.